There was a ~ three-fold increase in IFNγ secretion, a marker of tumor-specific T cell priming and activity, when splenocytes collected from the cured mice were stimulated by the two KRAS-mutant tumor cell lines, but no IFNγ induction was observed in the non-KRAS-mutant cell line. The gene discussed is KRAS; the disease is neoplasm.